

References

Abbott KC, Glanton CW, Trespalacios FC, et al (2004): Body mass index, dialysis modality, and survival: analysis of the United States Renal Data System Dialysis Morbidity and Mortality Wave II Study. *Kidney Int*; 65:597– 605.

Afzali B, Haydar AA, Vinen K, Goldsmith DJ, J Am Soc Nephrol (2004): From Finland to fatland: beneficial effects of statins for patients with chronic kidney disease. *Aug*; 15:2161-8.

Agarwal R (2004): Exploring the paradoxical relationship of hypertension with mortality in chronic hemodialysis. *Hemodialysis Int*; 8:207–213.

Agarwal R (2005): Hypertension and survival in chronic hemodialysis patients – past lessons and future opportunities. *Kidney Int*; 67:1–13.

Agarwal R, Andersen MJ, Bishu K, Saha C (2006): Home blood pressure monitoring improves the diagnosis of hypertension in hemodialysis patients. *Kidney Int* ; 69:900–906.

Agarwal R, Brim NJ, Mahenthiran J, Andersen MJ, Saha C (2006): Outof- hemodialysis-unit blood pressure is a superior determinant of left ventricular hypertrophy. *Hypertension*; 47:62–68.

Agarwal R, Peixoto AJ, Santos SF, Zoccali C (2006): Pre and post dialysis blood pressures are imprecise estimates of interdialytic ambulatory blood pressure. *Clin J Am Soc Nephrol* ;1:389–398.

Allon M (1995): Hyperkalemia in end-stage renal disease: mechanisms and management. *J Am Soc Nephrol* 1995 Oct;6(4):1134-42.

Albert MA, Danielson E, Rifai N, Ridker PM: PRINCE Investigators: Effect of statin therapy on C-reactive protein levels (2001): the pravastatin inflammation / CRP evaluation (PRINCE): a

randomized trial and cohort study. JAMA; 286:64–70. Am J Kidney Dis Feb;21(2):125-37.

Andrew Levey (2003): Chronic Kidney Disease: Progression, Tufts University School of Medicine, p 10.

Annual Report ,2005 (2006): ESRD clinical performance measures project. Am J Kidney Dis Suppl 2; 48:S1

Antman, EM, Anbe, DT, Armstrong, PW, et al (2004): ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation; 110:588.

Aslam N, Bernardini J, Fried L, Piraino B (2002): Large body mass index does not predict short-term survival in peritoneal dialysis patients. Perit Dial Int; 22:191– 6.

Attman P, Samuelsson O, Johansson A., Moberly JB, Alaupovic P (2003): Dialysis modalities and dyslipidemia. Kidney International Supplement ; 84:S110-112.

Avram MM, Bonomini LV, Sreedhara R, Mittman N (1996): Predictive value of nutritional markers (albumin, creatinine, cholesterol, and hematocrit) for patients on dialysis for up to 30 years. Am J Kidney Dis 28:910–917.

Avram MM, Mittman N, Myint MM, Fein P (2001): Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation. Am J Kidney Dis 38:1351–1357.

Barany P, Divino Filho JC, Bergstrom J (1997): High Creactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis 29:565- 568.

Becker AE, de Boer OJ, van Der Wal AC (2001): The role of inflammation and infection in coronary artery disease. Annu Rev Med; 52:289-297.

Becker B, Kronenberg F, Kielstein JT, Haller H, Morath C, Ritz E, Fliser D, MMKD Study Group (2005): Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol;16:1091–1098.

Beddhu S, Pappas LM, Ramkumar N, Samore M (2003): Effects of body size and body composition on survival in hemodialysis patients. J Am Soc Nephrol; 14:2366–2372

Benigni A; Corna D; Zoja C; Longaretti L; Gagliardini E; Perico N; Coffman TM; Remuzzi G (2004): Targeted deletion of angiotensin II type 1A receptor does not protect mice from progressive nephropathy of overload proteinuria. J Am Soc Nephrol Oct;15(10):2666-74.

Birgul N, Weise C, Kreienkamp HJ, Richter D (1999): Reverse physiology in drosophila: identification of a novel allatostatin-like neuropeptide and its cognate receptor structurally related to the mammalian somatostatin , galanin , opioid receptor family. EMBO J ;18:5892–5900.

Blacher J, Safar ME, Pannier B, Guerin AP, Marchais SJ, London GM (2002): Prognostic significance of arterial stiffness measurements in end stage renal disease patients. Curr Opin Nephrol Hypertens; 11:629–634.

Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM (2004): Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol ;15:2208–2218.

Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, Stenzel KH, Rubin AL (1998): Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis ;32:107–114.

Bonaa KH, Njolstad I, Ueland PM et al (2006): Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med; 354: 1578–1588

Bonnie C. H. Kwan and Srinivasan Beddhu (2007): A Story Half untold Adiposity, Adipokines and Outcomes in Dialysis Population Seminars in Dialysis—Vol 20, No 6 (November–December) 2007 pp. 493–497.

Bostom AG, Shemin D, Lapane KL, et al (1996): Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients. *Atherosclerosis*; 123:193–202.

Bredie S, Bosch F, Demacker P, Stalenhoef A, van Leusen R (2001): Effects of peritoneal dialysis with an overnight icodextrin dwell on parameters of glucose and lipid metabolism. *Peritoneal Dialysis International* :21: 275-281.

Caglar K, Fedje L, Dimmitt R, Hakim RM, Shyr Y, Ikizler TA (2002): Therapeutic effects of oral nutritional supplementation during hemodialysis. *Kidney Int*; 62:1054-1059.

Calabro P, Yeh ET (2005): The pleiotropic effects of statins. *Curr Opin Cardiol* ;20:541–546.

Chang JW, Yang WS, Min WK, Lee SK, Park JS, Kim SB (2002): Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. *AmJKidneyDis* ;39:81213–81217.

Charles R. Nolan (2005): Strategies for Improving Long-Term Survival in Patients with ESRD. *J Am Soc Nephrol* 16: S121.

Chertow GM, Burke SK, Raggi P: Treat to Goal Working Group (2002): Sevelamer sttenuates the progression of coronary and aortic calcification in hemodialysis patients. *Kidney Int*; 62:245–252.

Chertow GM; Ackert K; Lew NL; Lazarus JM; Lowrie EG (2000): Prealbumin is as important as albumin in the nutritional assessment of hemodialysis patients. *Kidney Int* 2000 Dec;58(6):2512-7

Cheung AK, Sarnak MJ, Yan G, Berkoben M, Heyka R, Kaufman A; Lewis J, Rocco M, Toto R, Windus D, Ornt D, Levey AS

(2004): Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. *Kidney Int Jun*;65(6):2380-9

Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, Teehan BP, Levey AS (2000): Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. *Kidney Int*; 58: 353–362.

Chung SH, Lindholm B, Lee HB (2000): Influence of initial nutritional status on continuous ambulatory peritoneal dialysis patient survival. *Perit Dial Int*;20:19 –26.

Cibulka R, Racek J, Vesela E (2005): The importance of L-carnitine in patients with chronic renal failure treated with hemodialysis. *Vnitr Lek* 51: 1108-1113.

Clinical practice guidelines for chronic kidney disease (2002): Evaluation, classification, and stratification. *Am J Kidney Dis* ; 39:S143.

Cohen LM; Germain MJ; Poppel DM (2003): Practical considerations in dialysis withdrawal: "to have that option is a blessing"; *JAMA* ,Apr 23-30;289(16):2113-9.

Comper WD and Osicka TM (2005): Detection of urinary albumin.

Csaba P. Kovesdy and Kamyar Kalantar-Zadeh(2007):The Reverse Epidemiology Controversy; *Seminars in Dialysis*—Vol 20, No 6 (November–December) p. 485

Danesh J, Collins R, Peto R (2000): Lipoprotein(a) and coronary heart disease: meta-analysis of prospective studies. *Circulation* ;102:1082–1085.

Daniels BS (1994): Increased albumin permeability in vitro following alterations of glomerular charge is mediated by the cells of the filtration barrier. *J Lab Clin Med Aug*;124(2):224-30.

Daugirdas JT, Ing T, Blake PG (2001): Hand book of dialysis, 3rd ed, Boston, L.W.W;23: 420-6.

Dawber TR, Meadors GF, Moore Jr FE (1951): Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health Nations Health 41:279–281

Dayal S, Lentz SR (2005): ADMA and hyperhomocysteinemia. Vasc Med; 10 (Suppl 1): S27-S33.

DB, Wilson PW (2003): Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. Jama 290:891–897.

De Lima JJ, Vieira ML, Abensur H, Krieger EM (2001): Baseline blood pressure and other variables influencing survival on haemodialysis of patients without overt cardiovascular disease. Nephrol Dial Transplant ;16:793–797.

DeFilippi C; Wasserman S; Rosanio S; Tiblier E; Sperger H; Tocchi M; Christenson R; Uretsky B; Smiley M; Gold J; Muniz H; Badalamenti J; Herzog C; Henrich W (2003): Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis.

Degoulet P, Legrain M, Reach I et al (1982): Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane Collaborative Study. Nephron ; 31:103-10.

Dember LM and Jaber BL (2006): Dialysis-related amyloidosis: late finding or hidden epidemic.Semin Dial.Mar-Apr;19(2):105-9

Dialysis Outcomes Quality Initiative Guidelines (2000): Clinical practice guidelines for nutrition in chronic renal failure. I. Adult guidelines A. Maintenance dialysis. Am J Kidney Dis; 35(Suppl 2):S19.

Ducloux D, Klein A, Kazory A et al (2006): Impact of malnutritioninflammation on the association between homocysteine and mortality. Kidney Int ; 69: 331–335

Ducloux D; Bresson-Vautrin C; Kribs M; Abdelfatah A; Chalopin JM (2002): C-reactive protein and cardiovascular disease in peritoneal dialysis patients. *Kidney Int* Oct;62(4):1417-22.

Duplain H, Burcelin R, Sartori C, Cook S, Egli M, Lepori M, Vollenweider P, Pedrazini T, Nicod P, Thorens B, Sherrer U (2001): Insulin resistance, hyperlipidemia and hypertension in mice lacking endothelial nitric oxide synthase. *Circulation*; 104: 342-345.

Dwyer JT; Larive B; Leung J; Rocco MV; Greene T; Burrowes J; Chertow GM; Cockram DB; Chumlea WC; Daugirdas J; Frydrych A; Kusek JW(2005): Are nutritional status indicators associated with mortality in the Hemodialysis (HEMO) Study *Kidney Int* Oct;68(4):1766-76.

Eiselt J, Racek J, Opatrny K Jr (1999): Free radicals and extracorporeal renal replacement therapy (in Czech). *Vnitr Lek* 45: 319-324.

Eiselt J, Racek J, Opatrny K Jr, Trefil L, Stehlek P (2006): The effect of intravenous iron on oxidative stress in hemodialysis patients at various levels of vitamin C. *Blood Purif* ; 24: 531-537.

Ejerblad E, Fored CM, Lindblad P, Fryzek J, Dickman PW, Elinder CG, McLaughlin JK and Nyren O (2004): Association between smoking and chronic renal failure in a nationwide population-based case-control study. *J Am Soc Nephrol* Aug;15(8):2178-85.

Eknoyan G, Beck GJ, Cheung AK, et al (2002): Effect of dialysis dose and membrane flux in maintenance hemodialysis. *N Engl J Med*; 347:2010-2019.

Erkan E, Devarajan P, Kaskel F (2002): Role of nitric oxide, endothelin-1, and inflammatory cytokines in blood pressure regulation in hemodialysis patients. *Am J Kidney Dis*; 40:76–81.

Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (2001): Executive Summary on the

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Panel III). JAMA; 285:2486–2497.

Fagugli RM, Reboli G, Quintaliani G, Pasini P, Ciao G, Cicconi B, Pasticci F, Kaufman JM, Buoncrisiani U (2001): Short daily hemodialysis: blood pressure control and left ventricular mass reduction in hypertensive hemodialysis patients. Am J Kidney Dis 38:371–376.

Fellstrom B, Zannad F, Schmieder R, Holdaas H, Jardine A, Rose H, Wilpshaar W (2005): AURORA Study Group: Effect of rosuvastatin on outcomes in chronic haemodialysis patients - design and rationale of the AURORA study. Curr Control Trials Cardio vasc Med 6:9.

Fink JC, Burdick RA, Kurth SJ, et al (1999): Significance of serum creatinine values in new end-stage renal disease patients. Am J Kidney Dis 34:694–701

Fleischman E, Teal N, Dudley J, May W, Bower JD, Salahudeen AK (1999): Influence of excess weight on mortality and hospital stay in 1346 hemodialysis patients. Kidney Int ; 55:1560-7.

Fleischmann EH, Bower JD, Salahudeen AK (2001): Risk factor paradox in hemodialysis: better nutrition as a partial explanation. ASAIO J; 47:74–81.

Florian Kronenberg, Katsunori Ikewaki, Juergen R. Schaefer, Paul Konig, and Hans Dieplinger (2007): Kinetic Studies of atherogenic lipoproteins in hemodialysis patients: Do They Tell Us More about Their Pathology? Seminars in Dialysis ;Vol 20, No 6 (November–December) : 554–560.

Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE (1996). Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int ;49:1379 –1385.

Foley RN (2004): Cardiac disease in chronic uremia.(2004) can it explain the reverse epidemiology of hypertension and survival in dialysis patients. Semin Dial ;17:275–278, 2004

Frischmann ME, Kronenberg F, Trenkwalder E, Schaefer J, Schweer H, Dieplinger B, Konig P, Ikewaki K, Dieplinger H (2007): In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. Kidney Int ;71:1036–1043.

Fung F, Sherrard DJ, Gillen DL, et al (2002): Increased risk for cardiovascular mortality among malnourished end-stage renal disease patients. Am J Kidney Dis; 40:307-314.

Gennari FJ and Segal AS (2002): Hyperkalemia: An adaptive response in chronic renal insufficiency. Kidney Int Jul;62(1):1-9.

Giordano M, De Feo P, Lucidi P, dePascale E, Giordano G, Infantone L, Zoccolo AM, Castellino P (2001): Increased albumin and fibrinogen synthesis in hemodialysis patients with normal nutritional status. J Am Soc Nephrol ;12:349–354.

Girndt M, Kaul H, Sester U, et al (2002): Anti-inflammatory interleukin-10 genotype protects dialysis patients from cardiovascular events. Kidney Int; 62:949-955.

GoAs, Chertow GM, FanD, McCullochCe, Hsu CY (2004): Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl JMed ;351:1296–1305.

Goldsmith DJ; Covic A (2001): Coronary artery disease in uremia: Etiology, diagnosis, and therapy. Kidney Int Dec;60(6):2059-78.

Golper TA, Goral S, Becker BN, Langman CB (2003): L-carnitine treatment of anemia. Am J Kidney Dis 41 (Suppl 4): S27-S34.

Gonzalez EA, Martin KJ (2001): Renal osteodystrophy. Rev Endocr Metab Disord; 2: 187-193.

Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB (2000): Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. *N Engl J Med*; 342: 1478–1483.

Greenland P, Knoll MD, Stamler J, Neaton JD, Dyer AR, Garside Guebre-Egziabher F, Bernhard J, Funahashi T, Hadj-Aissa A, Fouque D (2005): Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. *Nephrol Dial Transplant*; 20:129–134.

Guh JY, Chen HC, Chuang HY, et al (2002): Risk factors and risk for mortality of mild hypoparathyroidism in hemodialysis patients. *Am J Kidney Dis* 39:1245–1254.

Hakim RM and Lazarus JM (1995): Initiation of dialysis. *J Am Soc Nephrol* Nov;6(5):1319-28.

Hakim RM, Lowrie E (1999): Obesity and mortality in ESRD: is it good to be fat? *Kidney Int*; 55:1580 -1.

Heart Protection Study Collaborative Group (2002): MRC / BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals: a randomised placebo-controlled trial. *Lancet* ;360:7-22.
hemodialysis (in Czech). *Vnitr Lek*; 51: 1108-1113.

Hill JO, Melanson EL, Wyatt HT (2000): Dietary fat intake and regulation of energy balance: implications for obesity. *J Nutr (Suppl 2)*:284S–288S.

Hoffman MA, Lalla E, Lu Y, et al (2001): Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. *J Clin Invest*; 107:675– 83.

Holdaas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, Fauchald P, Gronhagen-Riska C, Madsen S, Neumayer H, Cole E, Maes B, Ambuhl P, Olsson AG, Hartmann A, Solbu DO, Pedersen TR (2003): the Assessment of LEscol in Renal

Transplantation (ALERT) Study Investigators: Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial. *Lancet* ;361:2024–2031.

HoldaasH, FellstromB, Cole E,NybergG, OlssonAG, Pedersen TR,Madsen S,Gronhagen-RiskaC,NeumayerH,Maes B,Ambuhl P,Hartmann A, Staffler B, Jardine AG (2005): The Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators: Long-term Cardiac Outcomes in Renal Transplant Recipients Receiving Fluvastatin: TheALERT Extension Study. *AmJ Transplant*; 5:2929–2936.

Homocysteine Studies Collaboration (2002): Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. *JAMA* ;288:2015– 2022.

Hork koS, Huttunen K, Kesaniemi YA (1995): Decreased clearance of lowdensity lipoprotein in uremic patients under dialysis treatment. *Kidney Int* ;47:1732–1740.

Horwich TB, Fonarow GC, HamiltonMA, MacLellanWR, WooMA, Tillisch JH (2001): The relationship between obesity and mortality in patients with heart failure. *J AmColl Cardiol* ;38:789–795.

Hsu CY and Chertow GM (2002): Elevations of serum phosphorus and potassium in mild to moderate chronic renal insufficiency. *Nephrol Dial Transplant* Aug;17(8):1419-25.

Hsu CY, McCulloch CE and Curhan GC (2002) : Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. *J Am Soc Nephrol* 2002 Feb;13(2):504-10.

Hulsewe KW, van Acker BA, von Meyenfeldt MF, Kalantar-zadeh et.al Soeters PB (1999): Nutritional depletion and dietary manipulation: Effects on the immune response. *World J Surg*; 23:536-544.

Ifudu O, Uribarri J, Rajwani I, et al (2002): Low hematocrit may connote a malnutrition-inflammation syndrome in hemodialysis patients. *Dial Transplant*; 31:845-878.

Ikewaki K, Schaefer JR, Frischmann ME, Okubo K, Hosoya T, Mochizuki S, Dieplinger B, Trenkwalder E, Schweer H, Kronenberg F, Koenig P, Dieplinger H (2005): Delayed in vivo catabolism of intermediatedensity lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis. *Arterioscler Thromb Vasc Biol*; 25:2615–2622.

Ikewaki K, Zech LA, Brewer HB Jr, Rader DJ (1996): ApoA-II kinetics in humans using endogenous labeling with stable isotopes: Slower turnover of apoA-II compared with the exogenous radiotracer method. *J Lipid Res*; 37:399-407.

Ikizler TA (2004): Protein and energy: recommended intake and nutrient supplementation in chronic dialysis patients. *Semin Dial*; 17: 471-478.

Imbeault P, Tremblay A, Simoneau JA, Joanisse DR (2002): Weight loss-induced rise in plasma pollutant is associated with reduced skeletal muscle oxidative capacity. *AmJ Physiol EndocrinolMetab* ;282:E574–E579.

Ingrosso D, Cimmino A, Perna AF, et al (2003): Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia. *Lancet*;361:1693– 1699.

Iseki K, Miyasato F, Tokuyama K, Nishime K, Uehara H, Shiohira Y, Sunagawa H, Yoshihara K, Yoshi S, Toma S, Kowatari T, Wake T, Oura T, Fukiyama K (1997). Low diastolic blood pressure, hypoalbuminemia, and risk of death in a cohort of chronic hemodialysis patients. *Kidney Int*;51:1212–1217.

Iseki K, Yamazato M, Tozawa M, Takishita S (2002): Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. *Kidney Int*; 61: 1887–1893.

Jager A, Kostense PJ, Nijpels G, et al (2001): Serum homocysteine levels are associated with the development of (micro)albuminuria: the Hoorn study. *Arterioscler Thromb Vasc Biol*; 21:74–81. *JAMA* 2003 Jul 16;290(3):353-9.

Jandacek RJ, Anderson N, Liu M, Zheng S, Yang Q, Tso P (2005): Effects of yo-yo diet, caloric restriction, and olestra on tissue distribution of hexachlorobenzene. *Am J Physiol Gastrointest Liver Physiol* ;288:G292–G299.

Johansen KL, Young B, Kaysen GA, Chertow GM (2004): Association of body size with outcomes among patients beginning dialysis. *Am J Clin Nutr*; 80:324–332.

JOHN KEVIN TUCKER (2004): Dyslipidemia in End-Stage Renal Disease *Nephrology rounds*. volume 2 : Issue 1 0.

Johnson DW, Herzig KA, Purdie DM, et al (2000): Is obesity a favorable prognostic factor in peritoneal dialysis patients? *Perit Dial Int*; 20:715–21.

K/DOQI Clinical Practice Guidelines (2000): nutrition in chronic renal failure. Guideline 23. *Am J Kidney Dis*; 35(Suppl 2):S19.

K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease (2002): Evaluation, Classification, Stratification. *Am J Kidney Dis*;39:S1-S266.

K/DOQI Clinical Practice Guidelines for bone metabolism and disease in chronic kidney disease (2003): *Am J Kidney Dis* ; 42:(Suppl 3):S1.

K/DOQI Clinical Practice Guidelines on Hypertension and antihypertensive agents in chronic kidney disease (2004): *Am J Kidney Dis*; 43:5(Suppl 1):S1.

K/DOQI Clinical Practice Guidelines and Recommendations (2006): Recommendations for anemia in Chronic Kidney Disease *Am J Kidney Dis* ; 47(suppl 3):S1.

K/DOQI Clinical practice guidelines (2006): nutrition in CRF: XII. Adult guidelines: Advanced chronic renal failure without dialysis (2006).

K/DOQI Clinical Practice Guidelines and Recommendations (2006): Hemodialysis adequacy Peritoneal Dialysis Adequacy Vascular Access. Am J Kidney Dis; 48(Suppl 1):S1.

Kaizu Y, Tsunega Y, Yoneyama T et al (1998): Overweight as another nutritional risk factor for the long-term survival of non-diabetic hemodialysis patients. Clin Nephrol ; 50:44-50.

Kaizu Y; Kimura M; Yoneyama T; Miyaji K; Hibi I; Kumagai H (1998): Interleukin-6 may mediate malnutrition in chronic hemodialysis patients. Am J Kidney Dis; Jan 31(1):93-100.

Kakiya R, Shoji T, Tsujimoto Y, Tatsumi N, Hatsuda S, Shinohara K, Kimoto E, Tahara H, Koyama H, Emoto M, Ishimura E, Miki T, Tabata T, Nishizawa Y (2006): Body fat mass and lean mass as predictors of survival in hemodialysis patients. Kidney Int; 70:549–556.

Kalantar-Zadeh K, Kleiner M, Dunne E, et al (1998): Total iron-binding capacity-estimated transferrin correlates with the nutritional Subjective Global Assessment in hemodialysis patients. Am J Kidney Dis; 31:263-272.

Kalantar-Zadeh K, Kopple JD (2001): Relative contributions of nutrition and inflammation to clinical outcome in dialysis patients. Am J Kidney Dis; 38:1343-1350.

Kalantar-Zadeh K, Kopple JD, Block G, Humphreys MH (2001): Association among SF-36 quality of life measures and nutrition, hospitalization, and mortality in hemodialysis. JAm Soc Nephrol; 12:2797-2806.

Kalantar-Zadeh K, Kopple JD, Block G, Humphreys MH (2001): A malnutrition-inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients. Am J Kidney Dis. Dec; 38(6):1251-63.

Kalantar-Zadeh K; Kopple JD (2001): Relative contributions of nutrition and inflammation to clinical outcome in dialysis patients. *Am J Kidney Dis* Dec;38(6):1343-50.

Kalantar-Zadeh K, Don BR, Rodriguez RA, Humphreys MH (2001): Serum ferritin is a marker of morbidity and mortality in hemodialysis patients. *Am J Kidney Dis* 37:564–572.

Kalantar-Zadeh K, Block G, Humphreys MH, et al (2003): Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. *Kidney Int*; 63:793–808.

Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD (2003): Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. *Am J Kidney Dis*; 42:864–881.

Kalantar-Zadeh K, Supasyndh O, Lehn RS, et al (2003): Normalized protein nitrogen appearance is correlated with hospitalization and mortality in hemodialysis patients with Kt/V more than 1.20. *J Ren Nutr* 13:10–17.

Kalantar-Zadeh K, Supasyndh O, Lehn RS, McAllister CJ, Kopple JD (2003): Normalized protein nitrogen appearance is correlated with hospitalization and mortality in hemodialysis patients with Kt/V greater than 1.20. *J Ren Nutr*; 13:15- 25.

Kalantar-Zadeh K, Kopple J (2003): Malnutrition as a cause of morbidity and mortality in dialysis patients, in Kopple J, Massry S (eds). *Nutritional Management of Renal Disease* (ed 2). Philadelphia, PA, Lippincott, Williams & Wilkins; pp 433-466.

Kalantar-Zadeh, K, Horwich TB, Fonarow GC, et al (2004): A low, rather than a high, serum LDL cholesterol is associated with increased mortality in hemodialysis patients even after controlling for inflammation. *J Am Soc Nephrol*; 15:173A (abstr).

Kalantar-Zadeh K, Block G, Humphreys MH, et al (2004): A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients. *J Am Soc Nephrol*; 15:442–453.

Kalantar-Zadeh K, Block G, Horwich T, Fonarow GC (2004) : Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol ;43:1439–1444.

Kalantar-Zadeh K, Fouque D, Kopple JD (2004): Outcome research, nutrition, and reverse epidemiology in maintenance dialysis patients. J Ren Nutr; 14:64–71.

Kalantar-Zadeh K, Kilpatrick RD, Kopple JD (2005): Reverse epidemiology of blood pressure in dialysis patients. Kidney Int; 67: 2067.

Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, Greenland S, Kopple JD (2005): Reverse epidemiology of hypertension and cardiovascular death in the hemodialysis population: the 58th annual fall conference and scientific sessions. Hypertension ;45:811–817.

Kalantar-Zadeh K (2005): Recent advances in understanding the malnutrition-inflammation-cachexia syndrome in chronic kidney disease patients: What is next?. Seminars in Dialysis. (Sep-Oct); 18(5):365-9.

Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG (2005): Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol Oct;16(10):3070-80. Epub Jul 20

Kalantar-Zadeh K, Stevenkel P, Bross R, Khawar OS, Rammohan M, Colman S, Benner D (2005): Kidney insufficiency and nutrient-based modulation of inflammation. Curr Opin Clin Nutr Metab Care; 8: 388- 396.

Kalantar-Zadeh K, Kilpatrick RD, Kopple JD (2005): Reverse epidemiology of blood pressure in dialysis patients. Kidney Int; 67: 2067.

Kalantar-Zadeh K, Kopple J, Kilpatrick R, McAllister C, Shinaberger C, Gjertson D, Greenland S (2005): Association of morbid obesity and weight change over time with cardiovascular survival in hemodialysis population. *Am J Kidney Dis*; 46:489–500.

Kalantar-Zadeh K, Kuwae N, Wu DY, Shantouf RS, Fouque D, Anker SD, BlockG, Kopple JD (2006): Associations of body fat and its changes over time with quality of life and prospective mortality in hemodialysis patients. *Am J Clin Nutr* ;83:202–210.

Kalantar-Zadeh K, Kopple JD (2006): Obesity paradox in patients on maintenance dialysis. *Contrib Nephrol* 151:57–69.

Kalantar-Zadeh K, Balakrishnan VS (2006): The kidney disease wasting: Inflammation, oxidative stress, and diet-gene interaction. *Hemodial Int* ;10:315–325.

Kalantar-Zadeh K, Horwich TB, Oreopoulos A, Kovesdy CP, Younessi H, Anker SD, Morley JE (2007): Risk factor paradox in wasting diseases. *Curr Opin Clin Nutr Metab Care* ;10:433-442.

Kaplan N (2001): Risk factor for atherosclerotic disease, in Braunwald E, Libby P (eds): *Heart Disease: A Textbook of Cardiovascular Medicine*. Philadelphia, PA, Saunders; pp 1010-1039

Kaul S, Zadeh AA, Shah PK (2006): Homocysteine hypothesis for atherothrombotic cardiovascular disease: not validated. *J Am Coll Cardiol* ;48:914–923.

Kaysen GA, Dubin JA, Muller HG, Rosales LM, Levin NW (2000): The acute-phase response varies with time and predicts serum albumin levels in hemodialysis patients. The HEMO Study Group. *Kidney Int*; 58:346-352.

Kaysen GA: The microinflammatory state in uremia (2001): Causes and potential consequences. *J Am Soc Nephrol* 12:1549-1557.

Kaysen GA, Chertow GM, Adhikarla R, Young B, Ronco C, Levin NW (2001): Inflammation and dietary protein intake exert competing effects on serum albumin and creatinine in hemodialysis patients. *Kidney Int*; 60:333-340.

Kaysen GA, Dubin JA, Muller HG, Mitch WE, Rosales LM, Levin NW (2002): Relationships among inflammation nutrition and physiologic mechanisms establishing albumin levels in hemodialysis patients. *Kidney Int* ;61:2240-2249.

Kaysen GA; Dubin JA; Muller HG; Rosales L; Levin NW; Mitch WE (2004): Inflammation and reduced albumin synthesis associated with stable decline in serum albumin in hemodialysis patients. *Kidney Int Apr*;65(4):1408-15

Kenchiah SE, Evans JC, Levy D et al (2002): Obesity and the risk of heart failure. *N Engl J Med*;347:305-13.

Kestenbaum B; Seliger SL; Gillen DL; Wasse H; Young B; Sherrard DJ; Weiss NS; Stehman-Breen CO (2004): Parathyroidectomy rates among United States dialysis patients: 1990-1999. *Kidney Int* 2004 Jan;65(1):282-8.

Klahr S, et al (2000): The progression of renal disease. *N Engl J Med*; 318: 1657-1666.

Klassen PS, Lowrie EG, Reddan DN, DeLong ER, Coladonato JA, Szczech LA, Lazarus JM, Owen WF Jr (2002): Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. *J Am Med Assoc*;287:1548 –1555.

Klaunig JE, XU Y, Isenberg JS, Bachowski S, Kolaja KL, Jiang J, Stevenson DE, Walborg EF Jr (1998): The role of oxidative stress in chemical carcinogenesis. *Environ Health Perspect* 106 (Suppl 1): 289-295.

Klausner, M.D (1997): Director of the National Cancer Institute, National Institutes of Health, U.S.Testimony on National Cancer Institute's FY 1998 Budget by Richard D. Department of Health and Human Services, Before the House Appropriations Committee,

Subcommittee on Labor, Health and Human Services, Education
and Related Agencies.
<http://www.hhs.gov/asl/testify/b970226b.html>, 1997

Kliwer SA, Lehmann JM, Willson TM (1999): Orphan nuclear receptors: shifting endocrinology into reverse. *Science*; 284:757–760.

Kopple JD (2001): Products of nitrogen metabolism. In: Massry SG, Glassock RJ, eds. *Textbook of nephrology*. 4th ed. Philadelphia: Lippincott Williams & Wilkins:1262–9.

Kopple JD (2005): the phenomenon of altered risk factor patterns or reverse epidemiology in persons with advanced chronic kidney failure. *Am J Clin Nutr*; 81:1257–1266.

Kovacic V, Roguljic L, Kovacic V (2003): Metabolic acidosis of chronically hemodialyzed patients. *Am J Nephrol*; 23: 158-164.

Kovesdy CP, Anderson JE, Kalantar-Zadeh K (2007): Paradoxical association between body mass index and mortality in men with CKD not yet on dialysis. *Am J Kidney Dis* ;49:581–591.

Kraut JA and Kurtz I (2005): Metabolic acidosis of CKD: diagnosis, clinical characteristics, and treatment. *Am J Kidney Dis* 45: 978-993.

Kronenberg F, Kuen E, Ritz E, Junker R, Konig P, Kraatz G, Lhotta K, Mann JFE, Muller GA, Neyer U, Riegel W, Riegler P, Schwenger V, Von Eckardstein A (2000): Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. *J Am Soc Nephrol* ;11:105–115.

Kronenberg F, Kuen E, Ritz E, Junker R, Konig P, Kraatz G, Lhotta K, Mann JFE, Muller GA, Neyer U, Riegel W, Riegler P, Kronenberg et al. Schwenger V, Von Eckardstein A (2002): Apolipoprotein A-IV serum concentrations are elevated in mild and moderate renal failure. *J Am Soc Nephrol* ;13:461–469.

Kronenberg F, Lhotta K, Konig P, Margreiter R, Dieplinger H, Utermann G (2003): Apolipoprotein(a) isoform-specific changes of lipoprotein(a) after kidney transplantation. *Eur J Hum Genet*;11:693–699.

Kushner I (2003): Acute phase proteins, in Rose B, Wellesley MA(eds): *Up To Date*. Boston, MA, Up To Date.

Kwan BC, Kronenberg F, Beddhu S, Cheung AK (2007): Lipoprotein metabolism and lipid management in chronic kidney disease. *J Am Soc Nephrol* ;18:1246–1261.

Landi F, Onder G, Gambassi G, Pedone C, Carbonin P, Bernabei R (2000): Body mass index and mortality among hospitalized patients. *Arch Intern Med* ;160:2641–2644.

Lazar AE, Smith MC, Rahman M (2004): Blood pressure measurement in hemodialysis patients. *Semin Dial*; 17:250–254.

Levey AS (1998): Controlling the epidemic of cardiovascular disease in chronic renal disease: Where do we start? *Am J Kidney Dis*; 32: S5–S13.

Levey AS, Eknoyan G (1999): Cardiovascular disease in chronic renal disease. *Nephrol Dial Transplant* 14: 828-833.

Leavy SF, McCullough K, Hecking E, Goodkin D, Port FK, Young EW (2001): Body mass index and mortality in healthier as compared with sicker haemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). *Nephrol Dial Transplant*; 16:2386-94.

Levey AS (2002) : K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. *Am J Kidney Dis*; 39 (Suppl 2): S1-S246.

Levey AS; Coresh J; Balk E; Kausz AT; Levin A; Steffes MW; Hogg RJ; Perrone RD; Lau J; Eknoyan G (2003): National Kidney Foundation practice guidelines for chronic kidney disease:

evaluation, classification, and stratification. *Ann Intern Med*, Jul 15;139(2):137-47.

Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, Zeeuw D, Hostetter TH, Lameire N, Eknoyan G (2005): Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int*; 67: 2089-2100.

Levin NW, Handelman GJ, Coresh J, Port FK, Kaysen GA (2007): Reverse epidemiology: a confusing, confounding and inaccurate term. *Seminars in Dialysis* ,Vol 20; No 6 (November–December): 586-92

Li Z, Lacson E Jr, Lowrie EG, Ofsthun NJ, Kuhlmann MK, Lazarus JM, Levin NW (2006): The epidemiology of systolic blood pressure and death risk in hemodialysis patients. *Am J Kidney Dis*; 48:606–615.

Liao D, Tan H, Hui R, et al (2006): Hyperhomocysteinemia decreases circulating high-density lipoprotein by inhibiting apolipoprotein A-I Protein synthesis and enhancing HDL cholesterol clearance. *Circ Res* ;99:598–606.

Lim PS, Wei YH, YU YL, Kho B (1999): Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. *Nephrol Dial Transplant* 14: 2680-2687.

Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, Tracy RP, Powe NR, Klag MJ (2004): Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. *JAMA*; 291:451–459.

London GM, Pannier B, Marchais SJ, Guerin AP (2000): Calcification and prevention of cardiovascular complication in chronic kidney disease patients. *Semin Nephrol* 24: 417–422.

London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H (2003): Arterial media calcification in end-stage renal

disease: Impact on all-cause and cardiovascular mortality. *Nephrol Dial Transplant*; 18: 1731–1740.

London GM, Pannier B, Agharazii M, et al (2004): Forearm reactive hyperemia and mortality in end-stage renal disease. *Kidney Int*; 65:700–704.

Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A, Klag MJ (2002): Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: The CHOICE Study. *J Am Soc Nephrol*; 13: 1918-1927.

Lonn E, Yusuf S, Arnold MJ, et al (2006): Homocysteine lowering with folic acid and B vitamins in vascular disease. *N Engl J Med*; 354:1567–1577.

Lopes AA; Bragg J; Young E; Goodkin D; Mapes D; Combe C; Piera L; Held P; Gillespie B; Port FK (2002): Depression as a predictor of mortality and hospitalization among hemodialysis patients in the United States and Europe. *Kidney Int* Jul;62(1):199-207

Loscalzo J (2006): Homocysteine trials – clear outcomes for complex reasons. *N Engl J Med*; 354:1629–1632.

Lowbeer C, Stenvinkel P, Pecoits-Filho R, et al (2003): Elevated cardiac troponin T in predialysis patients is associated with inflammation and predicts mortality. *J Intern Med* 253:153-160,

Lowrie EG, Lew NL (1990): Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. *Am J Kidney Dis* 15:458–482.

Lund RJ, Davies MR, Suresh M, Hruska KA (2006): New discoveries in the pathogenesis of renal osteodystrophy. *J Bone Miner Metab*; 24: 169-171.

Mallamaci F, Zoccali C, Tripepi G et al (2002): Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. *Kidney Int*; 61: 609–614.

Malluche HH and Monier-Faugere MC (1992): Risk of adynamic bone disease in dialyzed patients. *Kidney Int Suppl* 1992 Oct;38:S62-7.

Mann JF, Gerstein HC, Pogue J, et al (2001): Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. *Ann Intern Med* 134:629–636.

Maru S, Van der Schouw YT, Gimber CH, Grobbee DE, Peeters PH (2004): Body mass index and short-term weight change in relation to mortality in Dutch woman after age 50 y. *Am J Clin Nutr*; 80:231-6.

Mason NA, Bailie GR, Satayathum S, Bragg-Gresham JL, Akiba T, Akizawa T, Combe C, Rayner HC, Saito A, Gillespie BW, Young EW (2004): HMG-Co-Enzyme A Reductase Inhibitor Use Is Associated With Mortality Reduction in Haemodialysis Patients. *Am J Kidney Dis*; 45:119–126.

Massry SG (2001): Parathyroid hormone as a uremic toxin. In: Massry SG, Glassock RJ, eds. *Textbook of nephrology*. 4th ed. Philadelphia: Lippincott Williams & Wilkins:1221–44.

Matsuoka M, Iseki K, Tamashiro M, Fujimoto N, Higa N, Touma T, Takishita S (2004): Impact of high coronary artery calcification score (CACS) on survival in patients on chronic hemodialysis. *Clin Exp Nephrol*; 8: 54-58.

McCusker FX, Teehan BP, Thorpe KE, Keshaviah PR, Churchill DN (1996): for the Canada-USA (CANUSA) Peritoneal Dialysis Study Group. How much peritoneal dialysis is necessary for maintaining a good nutritional status? *Kidney Int*; 56(suppl):S56–61.

McDonald SP, Collins JF, Johnson DW (2003): Obesity is associated with worse peritoneal dialysis outcomes in the Australia

and New Zealand patient populations. J Am Soc Nephrol; 14:2894 – 901.

Mehrotra R, Kopple J (2003): Causes of protein-energy malnutrition in chronic renal failure, in Kopple J, Massry S (eds). Nutritional Management of Renal Disease (ed 2). Philadelphia, PA, Lippincott, Williams & Wilkins; pp 167-182

Menon V, Wang X, Greene T et al (2005): Homocysteine in chronic kidney disease: effect of low protein diet and repletion with B vitamins. Kidney Int; 67: 1539–1546

Menon V, Sarnak MJ, Greene T, et al (2006): Relationship between homocysteine and mortality in chronic kidney disease. Circulation ;113:1572– 1577.

Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, Kolloch R, Benetos A, Pepine CJ (2006): Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med; 144:884–893.

Michal Chmielewski, Juan Jesus Carrero, Louise Nordfors, Bengt Lindholm and Peter Stenvinkel (2008). Lipid disorders in chronic kidney disease: reverse epidemiology and therapeutic approach. JNephrol ; 21: 635-644.

Mikael LG, Genest J Jr, Rozen R (2006): Elevated homocysteine reduces apolipoprotein A-I expression in hyperhomocysteinemic mice and in males with coronary artery disease. Circ Res; 98:564–571.

Miyata T, Inagi R, Kurokawa K (1999): Diagnosis, pathogenesis, and treatment of dialysis-related amyloidosis. Miner

Mohamed-Ali V, Goodrick S, Bulmer K, Holly JM, Yudkin JS, Coppack SW (1999): Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo. AmJ Physiol ;277:E971–E975.

Mohamed E. Suliman, Bengt Lindholm, Peter Ba'ra'ny, Abdul Rashid Qureshi, and Peter Stenvinkel (2007). Homocysteine-Lowering Is Not a Primary Target for Cardiovascular Disease Prevention in Chronic Kidney Disease Patients. *Seminars in Dialysis*—Vol 20, No 6 (November–December) pp. 523–529.

National Kidney Foundation (2003): KDOQI Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease. *Am J Kidney Dis*; 41 (Suppl. 3):S1–S92.

National Kidney Foundation (2004): K/DOQI, clinical practice guidelines for bone metabolism and disease in chronic kidney disease, guideline 7.

National Kidney Foundation (2005): K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. *Am J Kidney Dis* 45:S1–S153,154.

Nedeljkovic ZS, Gakce N, Loscalzo J (2003): Mechanisms of oxidative stress and vascular dysfunction. *Postgrad Med J*; 79: 195–199.

Ninomiya T, Kiyohara Y, Kubo M, et al (2004): Hyperhomocysteinemia and the development of chronic kidney disease in a general population, the Hisayama study. *Am J Kidney Dis*; 44:437–445.

Nishizawa Y, Shoji T, Ishimura E, Inaba M, Morii H (2001): Paradox of risk factors for cardiovascular mortality in uremia: is a higher cholesterol level better for atherosclerosis in uremia? *Am J Kidney Dis* ; 38(4 Suppl. 1):S4–S7.

Nishizawa Y, Shoji T, Kakiya R, Tsujimoto Y, Tabata T, Ishimura E, Nakatani T, Miki T, Inaba M (2003): Non-high-density lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with end-stage renal disease. *Kidney Int* ; 63(Suppl. 84):117–120

Nubé MJ, Vervloet MG (2000): Proatherogene veranderingen door hemodialyse: mogelijk een gevolg van bio-incompatibiliteit. Ned Tijdschr Geneesk ;53:2540-3.

Nuhad Ismail (2007): Indications for initiation of dialysis in chronic renal failure, up to date 2007

Oberg BP; McMenamin E; Lucas FL; McMonagle E; Morrow J; Ikizler TA; Himmelfarb J (2004): Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int Mar;65(3):1009-16.

Oh Ms, Uriparri J, Weinstein J, Schreiper M, Kamel KS, Kraut JA, Madias NE, Laskime (2004):What unique acid-base considerations exist in dialysis patients? Semin Dial; 17: 351-364.

Ohtake T; Kobayashi S; Moriya H; Negishi K; Okamoto K; Maesato K; Saito S (2005):High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy: an angiographic examination. J Am Soc Nephrol Apr;16(4):1141-8.

O'Seaghdha CM; Foley RN (2005): Septicemia, access, cardiovascular disease, and death in dialysis patients. Perit Dial Int. Nov-Dec;25(6):534-40.

Ottosson P, Attman P-O, Knight-Gibson C, et al (2001): Do high flux dialysis membranes affect renal dyslipidemia ?.ASAIO Journal ;47:229-234.

Pecoits-Filho R, Lindholm B, Stenvinkel P (2002): The malnutrition, inflammation, and atherosclerosis (MIA) syndrome, The heart of the matter. Nephrol Dial Transplant suppl 11 ;17:S28-S31.

Pecoits-Filho R, Stenvinkel P, Marchlewska A, et al (2003): A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Int Suppl ; 84:S172-S176.

Pegoraro AA, Gudehithlu KP, Cabrera E, Shankar R, Arruda JA, Dunea G, Singh AK (2002): Handling of low-density lipoprotein by the renal tubule: release of fragments due to incomplete degradation. *J Lab Clin Med* ; 139:372–378.

Perna AF, Capasso R, Lombardi C, Acanfora F, Satta E, Ingrosso D (2005): Hyperhomocysteinemia and macromolecule modifications in uremic patients. *Clin Chem Lab Med* 43: 1032-1038.

Peter Stenvinkel, Juan Jesu´s Carrero, Jonas Axelsson, Bengt Lindholm, Olof Heimbürger, and Ziad Massy (2008). Emerging Biomarkers for Evaluating Cardiovascular Risk in the Chronic Kidney Disease Patient: How Do New Pieces Fit into the Uremic Puzzle; *Clin J Am Soc Nephrol* 3: 505-521

Pietzsch J, Lattke P, Julius U (2000): Oxidation of apolipoprotein B-100 in circulating LDL is related to LDL residence time. In vivo insights from stable-isotope studies. *Arterioscler Thromb Vasc Biol*; 20:E63– E67.

Plutzky J (2003): Medicine. PPARs as therapeutic targets: reverse cardiology .*Science*; 302:406-407.

Port FK, Ashby VB, Dhingra RK, Roys EC, Wolfe RA (2002): Dialysis dose and body mass index are strongly associated with survival in hemodialysis patients. *J Am Soc Nephrol*; 13:1061-1066.

Prinsen BH, Rabelink TJ, Romijn JA, Bisschop PH, De Barse MM, De Boer J, Van Haeften TW, Barrett PH, Berger R, de Sain-van der Velden MG (2004): A broad-based metabolic approach to study VLDL apoB100 metabolism in patients with ESRD and patients treated with peritoneal dialysis. *Kidney Int* ; 65:1064–1075.

Proudfoot D, Shanahan CM (2001): Biology of calcification in vascular cells: Intima versus media. *Herz*; 26: 245–251.

Pupim LB ;Kent P; Caglar K; Shyr Y; Hakim RM and Ikizler TA (2002): Improvement in nutritional parameters after initiation of chronic hemodialysis. *Am J Kidney Dis* Jul;40(1):143-51

Qunibi WY (2005): Dyslipidemia and progression of cardiovascular calcification (CVC) in patients with end-stage renal disease (ESRD). *Kidney Int*; 95(Suppl): S43–S50.

Qureshi AR, Alvestrand A, Divino-Filho JC, et al (2002): Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. *JAm Soc Nephrol*; 13: suppl 1,S28-S36.

Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM (2002):Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? *J Am Coll Cardiol*; 39: 695–701.

Rahman M, Dixit A, Donley V, Gupta S, Hanslik T, Lacson E, Ogundipe A, Weigel K, Smith MC (1999): Factors associated with inadequate blood pressure control in hypertensive hemodialysis patients. *Am J Kidney Dis*; 33:498–506.

Ramkumar N, Pappas LM, Beddhu S (2005): Effects of body size and body composition on survival in peritoneal dialysis patients. *Perit Dial Int*; 25:461–469.

Rao M, Guo D, Perianayagam MC,Tighiouart H, Jaber BL, Pereira BJ, Balakrishnan VS (2005): Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. *Am J Kidney Dis* Feb;45(2):324-33

RauchhausM, Coats AJ, Anker SD (2000): The endotoxin-lipoprotein hypothesis. *Lancet*; 356:930–933.

Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C (2005): Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. *J Am Soc Nephrol*; 16: 2254-2256.

Remuzzi G, Schieppati A, Ruggenenti P(2002): Nephropathy in patients with type 2 diabetes. *N Engl J Med*;346:1145-51.

Ridker PM, Rifai N, Rose L, Buring JE, Cook NR (2002): Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. *N Engl J Med*; 347:1557-1565.

Rigalleau V, Gin H (2005): Carbohydrate metabolism in uremia. *Curr Opin Clin Nutr Metab Care*; 8: 463-869.

Riksen NP, Rongen GA, Blom HJ, et al (2003): Potential role for adenosine in the pathogenesis of the vascular complications of hyperhomocysteinemia. *Cardiovasc Res*; 59:271–276.

Robert N. Foley and Rajiv Agarwal (2007). Hypertension Is Harmful to Dialysis Patients and Should Be Controlled. *Seminars in Dialysis—Vol 20, No 6 (November–December)* pp. 518–522.

Rose, BD, Post, TW (2001): *Clinical Physiology of Acid-Base and Electrolyte Disorders*, 5th ed, McGraw-Hill, New York, pp. 913-919.

Royal College of Physicians (2006): joint Specialty Committee on Renal Medicine of the Royal College of Physicians and the Renal Association, and the Royal College of General Practitioners. Chronic kidney disease in adults: UK guidelines for identification, management and referral. London Cited 28 April 2008.

Ruilope LM, Salvetti A, Jamerson K, et al (2001): Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. *J Am Soc Nephrol* 12:218–225.

Sadek T; Mazouz H; Bahloul H; Oprisiu R; El Esper N; El Esper I; Boitte F; Brazier M; Moriniere P; Fournier A (2003): Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study. *Nephrol Dial Transplant* 2003

Mar;18(3):582-8.

Sakurai T (2005): Reverse pharmacology of orexin. from an orphan GPCR to integrative physiology. *Regul Pept* ;126:3–10.

Santoro A (2002): Anemia in renal insufficiency. *Rev Clin Exp Hematol Suppl* 1: 12-20.

Sarnak MJ, Levey AS, Schoolwerth AC et al (2003): Kidney disease as a risk factor for development of cardiovascular disease. *Circulation*; 108:2154-69.

Schmidt D and Salahudeen A (2007): The obesity-survival paradox in hemodialysis patients: why do overweight hemodialysis patients live longer? *Nutr Clin Pract*; 22:11–15.

Scholze A, Rinder C, Beige J, Riezler R, Zidek W, Tepel M (2004): Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure. *Circulation*; 109:369–374.

Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, Mall G, Amann K (2000): Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. *Nephrol Dial Transplant*; 15: 218–223.

Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ, Stehman-Breen CO (2002): HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. *Kidney Int*; 61: 297–304.

Sesso R; Santos AP; Nishida SK; Klag MJ; Carvalhaes JT; Ajzen H; Ramos OL; Pereira AB (1992): Prediction of steroid responsiveness in the idiopathic nephrotic syndrome using urinary retinol-binding protein and beta-2-microglobulin. *Ann Intern Med* Jun 1;116(11):905-9.

Shinohara K, Shoji T, Emoyo M, Tahara H, Koyama H, Ishimura E, Miki T, Tabata T, Nishizawa Y (2002): Insulin resistance as an

independent predictor of cardiovascular mortality in patients with end-stage renal disease. *J Am Soc Nephrol*; 13: 1894-1900.

Shoji T, Nishizawa Y, Kawagishi T, Kawasaki K, Taniwaki H, Tabata T, Inoue T, Morii H (1998): Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. *J Am Soc Nephrol* ;9:1277–1284.

Shoji T, Fukumoto M, Kimoto E, Shinohara K, Emoto M, Tahara H, Koyama H, Ishimura E, Nakatani T, Miki T, Tsujimoto Y, Tabata T, Nishizawa Y (2002): Antibody to oxidized low-density lipoprotein and cardiovascular mortality in end-stage renal disease. *Kidney Int* ; 62:2230–2237.

Singhal R and Brimble KS (2006): Thromboembolic complications in the nephrotic syndrome: Pathophysiology and clinical management *Thromb Res*;118(3):397-407,Jun 28.

Snyder JJ, Foley RN, Gilbertson DT, Vonesh EF, Collins AJ (2003): Body size and outcomes on peritoneal dialysis in the United States. *Kidney Int*; 64:1838–44.

Snyder S and Pender Graph B (2005): Detection and evaluation of chronic kidney disease. *Am Fam Physician* 72: 1723-1732.

Sprague SM; Llach F; Amdahl M; Taccetta C; Batlle D (2003): Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. *Kidney Int Apr*; 63(4):1483-90.

Stack AG, Murthy BV, Molony DA (2004): Survival differences between peritoneal dialysis and hemodialysis among “large” ESRD patients in the United States. *Kidney Int*; 65:2398–408.

Stenvinkel P, Holmberg I, Heimbürger O, Diczfalussy U (1998): A study of plasminogen as an index of oxidative stress in patients with chronic renal failure. Evidence of increased oxidative stress in malnourished patients. *Nephrol Dial Transplant*; 13:2594-2600.

Stenvinkel P, Heimbürger O, Lindholm B, Kaysen GA, Bergström J (2000): Are there two types of malnutrition in chronic renal

failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). *Nephrol Dial Transplant*; 15:953-960.

Stenvinkel P; Barany P; Heimbürger O; Pecoits-Filho R; Lindholm B (2002): Mortality, malnutrition, and atherosclerosis in ESRD: What is the role of interleukin-6?. *Kidney Int* 2002 May;61 Suppl 80:103-8.

Stenvinkel P, Heimbürger O, Jørgensen T (2002): Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients association with Chlamydia pneumonia seropositivity. *Am J Kidney Dis*; 39:274–282.

Stenvinkel P, Karimi M, Johansson S, et al (2007): DNA hypermethylation is an independent predictor of all-cause and cardiovascular mortality and related to inflammation in chronic kidney disease. *J Intern Med*; 261:488–499.

Stidley CA, Hunt WC, Tentori F, Schmidt D, Rohrscheib M, Paine S, Bedrick EJ, Meyer KB, Johnson HK, Zager PG (2006): Medical Directors of Dialysis Clinic Inc.: changing relationship of blood pressure with mortality over time among hemodialysis patients. *J Am Soc Nephrol* ;17:513–520.

Streetz KL, Wustefeld T, Klein C, Manns MP, Trautwein C (2001): Mediators of inflammation and acute phase response in the liver. *Cell Mol Biol (Noisy-le-grand)* 47:661- 673.

Suliman ME, Lindholm B, Barany P, Bergström J (2001): Hyperhomocysteinemia in chronic renal failure patients: relation to nutritional status and cardiovascular disease. *Clin Chem Lab Med*; 39: 734-738.

Suliman ME, Barany P, Kalantar-Zadeh K, et al (2005): Homocysteine in uraemia , a puzzling and conflicting story. *Nephrol Dial Transplant* ;20:16–21.

Suliman ME, Stenvinkel P, et al (2006): Hyperhomocysteinemia, malnutrition, and inflammation in ESRD patients. *Semin Nephrol*;

26:14–19.

Suliman M, Stenvinkel P, Qureshi AR, et al (2007): The reverse epidemiology of plasma total homocysteine as a mortality risk factor is related to the impact of wasting and inflammation. *Nephrol Dial Transplant*; 22:209–217.

Swaminathan B (2003): The potential for linking clinical isolates to food isolates from routine surveillance samples and the epidemiological implications. :Chicago, IL: Food borne & Diarrheal Diseases Branch, Centers for Disease Control & Prevention, Div. of Bacterial & Mycotic Diseases, Atlanta, GA.

Takahashi A, Takase H, Toriyama T, Sugiura T, Kurita Y, Ueda R, Dohi Y (2006): Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis – a randomized study. *Nephrol Dial Transplant* ;21.

Tattersall J, Greenwood R, Farrington K (1995): Urea kinetics and when to commence dialysis. *Am J Nephrol* 15:283–289.

Tayeb JS; Provenzano R; El-Ghoroury M; Bellovich K; Khairullah Q; Pieper D; Morrison L; Calleja Y (2000): Effect of biocompatibility of hemodialysis membranes on serum albumin levels *Am J Kidney Dis* Apr;35(4):606-10

Tepel M, van der GM, Statz M, Jankowski J, Zidek W (2003): The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. *Circulation*; 107: 992–995.

Testa A; Beaud JM (1998): The other side of the coin: interdialytic weight gain as an index of good nutrition. *Am J Kidney Dis* May;31(5):830-4.

Theodore W Post and MD Burton D Rose, MD (2007): Urinalysis in the diagnosis of renal disease. Up to date 2007.

Thomson Scientific Solutions (2006): Essential Science Indicators. Emerging Research Fronts in Feb. (<http://www.esi-topics.com/erf/february2006.html>),

Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, Craven T, West M (2004): Effect of pravastatin on cardiovascular events in people with chronic kidney disease. *Circulation* ; 110:1557–1563.

Toole JF, Malinow MR, Chambless LE, et al (2004): Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. *JAMA*; 291:565–575.

Trayhurn P, Wood IS (2005): Signalling role of adipose tissue: adipokines and inflammation in obesity. *Biochem Soc Trans*; 33:1078–1081.

Trespalacios FC, Taylor AJ, Agodoa LY, Abbott KC (2002): Incident acute coronary syndromes in chronic dialysis patients in the United States. *Kidney Int Nov*;62(5):1799-805

Tronche F, Casanova E, Turiault M, Sahly I, Kellendonk C (2002): When reverse genetics meets physiology: the use of site-specific recombinases in mice. *FEBS Lett* ;529:116–121.

United States Renal Data System (2003): USRD 2003 Annual Data Report; Atlas of End Stage Renal Diseases in the United States. Bethesda, Md: Maryland National Institute of Health, National Institute of Diabetes, and Digestive and Kidney Diseases.

United States Renal Data System (USRDS). Excerpts from USRDS 2004 Annual Data Report (2005): U.S. Department of Health and Human Services. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. *Am J Kidney Dis*; 45 (Suppl 1):S1.

United States Renal Data System (2006): Excerpts from USRDS 2005 Annual Data Report. U.S. Department of Health and Human

Services. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Am J Kidney Dis ; 47(Suppl 1):S1.

United States Renal Data System (2006): USRDS 2005 Annual Data Report. ESRD clinical performance measures project. Am J Kidney Dis suppl 2; 48:S1

Uribarri J (2000) : Acidosis in chronic renal insufficiency. Seminars in Dialysis Jul-Aug;13(4):232-4.

Urquhart BL, Freeman DJ, Spence JD, et al (2007): The effect of mesna on plasma total homocysteine concentration in hemodialysis patients. Am J Kidney Dis; 49:109–117.

Van Den Hoogen PCW, Feskens EJM, Nagelkerke NJD, et al (2000): The Seven Countries Study research group. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. N Engl J Med; 342:1– 8.

Vanrenterghem Y, Barany P, Mann JF, Kerr PG, Wilson J, Baker NF, Gray SJ (2002): Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int Dec;62(6):2167-75.

Vernaghlione L, Cristofano C, Muscogiuri P, Chimienti S (2004): Does atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis? Am J Kidney Dis; 43:471–478.

Viatte S, Alves PM, Romero P (2006): Reverse immunology approach for the identification of CD8 T-cell-defined antigens: advantages and hurdles. Immunol Cell Biol; 84:318–330.

Wald DS, Law M, Morris JK (2002): Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ; 325: 1202

Wallen MD, Radhakrishnan J, Appel G, Hodgson ME, Pablos Mendez (2001): An analysis of cardiac mortality in patients with

new-onset end-stage renal disease in New York State; Clinical Nephrology Feb;55(2):101-8.

Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E (2005): German Diabetes and Dialysis Study Investigators: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med ; 353:238-248.

Weiner DE, Sarnak MJ (2004): Managing dyslipidemia in chronic kidney disease. J Gen Intern Med Oct;19:1045-52.

Weir MR and Fink JC (2005): Salt intake and progression of chronic kidney disease: an overlooked modifiable exposure. Am J Kidney Dis Jan;45(1):176-88.

Wellen KE, Hotamisligil GS (2005): Inflammation, stress, and diabetes. J Clin Invest; 115:1111–1119.

Whitehead JP, Richards AA, Hickman IJ, Macdonald GA, Prins JB (2006): Adiponectin—a key adipokine in the metabolic syndrome. Diabetes Obes Metab; 8:264–280.

William L Henrich (2007): Patient survival and maintenance dialysis; up to date 2007

Wiviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E (2005): PROVE IT-TIMI 22 Investigators. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol ; 46:1411–1416.

Wong JS, Port FK, Hulbert-Shearon TE, et al (1999): Survival advantage in Asian American end-stage renal disease patients. Kidney Int; 55: 2515–23.

Wronski EM, Hornberger JM, Zehnder JL, et al (2004): Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol; 15:420–426.

Yamauchi T, Kuno T, Takada H, Nagura Y, Kanmatsuse K, Takahashi S (2003): The impact of visceral fat on multiple risk factors and carotid atherosclerosis in chronic haemodialysis patients. *Nephrol Dial Transplant*; 18:1842–1847.

Yeun JY, Levine RA, Mantadilok V, Kaysen GA (2000): Malnutrition-Inflammation Complex C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. *Am J Kidney Dis*; 35:469- 476.

Yu WC, Lin YP, Lin IF, Chuang SY, Chen CH (2006): Effect of ramipril on left ventricular mass in normotensive hemodialysis patients. *Am J Kidney Dis*; 47:478–484.

Zager PG, Nikolic J, Brown RH, Campbell MA, Hunt WC, Peterson D, Van Stone J, Levey A, Meyer KB, Klag MJ, Johnson HK, Clark E, Sadler JH, Teredesai P(1998). “U” curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. *Kidney Int.* ;54:561–569.

Zoccali C; Bode-Boger S; Mallamaci F; Benedetto F; Tripepi G; Malatino L; Cataliotti A; Bellanuova I; Fermo I; Frolich J; Boger R (2001): Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. *Lancet* 2001 Dec 22-29; 358(9299):2113-7.

Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Buemi M, Nicocia G, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y (2002): Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. *J Am Soc Nephrol*; 13:134–141.

Zoccali C (2006): Asymmetric dimethylarginine (ADMA) A cardiovascular risk factor on the move . *J Hypertens*; 24:611–619.

Zoccali C, Mallamaci F (2006): Homocysteine and risk in end-stage renal disease: a matter of context. *Kidney Int*; 69:204–206.

Zoccali C, Testa A, Spoto B, et al (2006): Mendelian randomization: a new approach to studying epidemiology in ESRD. Am J Kidney Dis; 47:332-341.

Zoungas S, McGrath BP, Branley P, et al (2006): Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial. J Am Coll Cardiol; 47:1108–1116.